SAN DIEGO, Sept. 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society. This meeting will be held October 1-5, 2011 in Orlando, FL at the Orlando World Center Marriott.
Details on the presentation times are as follows:Monday, October 3, 2011 – Abstract #598-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Robert Chilton, DO; University of Texas Health Science Center, San Antonio, TX, USA.Title: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart FailureMonday, October 3, 2011 – Abstract #605-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Ken Fujioka, MD; Scripps Clinic, La Jolla, CA, USA.Title: Completion of 56 Weeks of Naltrexone SR/Bupropion SR Combination Therapy Increases Likelihood of Achieving Improvements in Markers of Cardiometabolic Risk Associated with Clinically Meaningful Weight LossMonday, October 3, 2011 – Abstract #607-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Patrick O'Neil, PhD; Medical University of South Carolina, Charleston, SC, USA.Title: Naltrexone SR/Bupropion SR and Intensive Behavioral Modification Combination Increases the Likelihood of Achieving Early and Sustained Weight Loss and Associated Improvement in Markers of Cardiometabolic RiskMonday, October 3, 2011 – Abstract #49-OR, Presentation time 3:15-4:45PM EDT, "Intervention and Clinical Studies - Surgery/Drugs" SessionPresenter: Gene-Jack Wang, MD; Brookhaven National Laboratory, Upton, NY Title: Reduced responses to food cue after combined therapy with naltrexone and bupropionAbout ContraveContrave, an investigational combination therapy of naltrexone HCl and bupropion HCl, was studied for its ability to help people with obesity initiate and sustain weight loss of at least 5 percent of their starting body weight in one year. Contrave was submitted for U.S. regulatory approval in March 2010. The original submission was based on multiple clinical trials that evaluated Contrave in more than 4500 patients. Orexigen received a Complete Response letter from FDA on January 31, 2011.
About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved